Company intelligence / Profile preview

Novo Cellular Medicine Institute

Pune, Maharashtra?, India

Ownership: Private
Development stage: Other

Overview

The company has treated over 100 patients since 2013 using investigational protocols for chronic inflammatory/neurodegenerative conditions. Most data are anecdotal or from early-phase studies; no large-scale published pivotal trial results available as of June 2025. All protocols are IRB-approved but not FDA-approved therapies.

Therapeutic areas: OncologyImmunologyNeurologyPulmonology
Modalities: Stem cell therapyMesenchymal stem cell therapyHematopoietic stem cell therapyCell therapyRegenerative medicine approaches
Industry: Biotech

Drug pipeline

3 assets

allogeneic human umbilical cord tissue-derived mesenchymal stem cells

2 more assets in the full pipeline.

Request access →

Partnerships

NCORD Biotech Limited (India) (joint venture partner for laboratory operations)

Beyond the preview

Go deeper on Novo Cellular Medicine Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novo Cellular Medicine Institute.

Explore the full profile